1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption

Over the past decade, new emerging tobacco and nicotine-delivery products have changed the tobacco landscape. Especially, electronic cigarettes (ECs) have been suggested to be considered for tobacco harm reduction, reinforcing the need to identify novel biomarkers of exposure (BoE) specific to the E...

Full description

Bibliographic Details
Main Authors: Therese Burkhardt, Nikola Pluym, Gerhard Scherer, Max Scherer
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Separations
Subjects:
Online Access:https://www.mdpi.com/2297-8739/8/10/180
_version_ 1797513122253111296
author Therese Burkhardt
Nikola Pluym
Gerhard Scherer
Max Scherer
author_facet Therese Burkhardt
Nikola Pluym
Gerhard Scherer
Max Scherer
author_sort Therese Burkhardt
collection DOAJ
description Over the past decade, new emerging tobacco and nicotine-delivery products have changed the tobacco landscape. Especially, electronic cigarettes (ECs) have been suggested to be considered for tobacco harm reduction, reinforcing the need to identify novel biomarkers of exposure (BoE) specific to the EC use as this would complement exposure assessment and product compliance monitoring. Therefore, a sensitive LC-MS/MS method for the quantification of 1,2-propylene glycol (PG) and glycerol (G), the main e-liquid constituents, was established. PG and G were analyzed in plasma and urine samples from a clinical study comparing five nicotine product user groups, users of combustible cigarettes (CC), electronic cigarettes (EC), heated tobacco products (HTP), oral tobacco (OT), and oral/dermal nicotine delivery products (used for nicotine replacement therapy, NRT) with a control group of non-users (NU). Data demonstrate significantly elevated PG levels in urine and plasma in EC users compared to users of CC, HTP, NRT, OT as well as NU. In addition, PG in plasma and urine of vapers significantly correlated with nicotine (plasma) and total nicotine equivalents (urine), biomarkers reflecting product consumption, emphasizing the high specificity of PG as a BoE for EC consumption. We therefore suggest the use of PG as BoE in urine and/or plasma in order to monitor EC use compliance in exposure assessments.
first_indexed 2024-03-10T06:12:12Z
format Article
id doaj.art-3f25fea676c74e8bbb7e1460407c59d5
institution Directory Open Access Journal
issn 2297-8739
language English
last_indexed 2024-03-10T06:12:12Z
publishDate 2021-10-01
publisher MDPI AG
record_format Article
series Separations
spelling doaj.art-3f25fea676c74e8bbb7e1460407c59d52023-11-22T20:00:15ZengMDPI AGSeparations2297-87392021-10-0181018010.3390/separations81001801,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette ConsumptionTherese Burkhardt0Nikola Pluym1Gerhard Scherer2Max Scherer3ABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152 Planegg, GermanyABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152 Planegg, GermanyABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152 Planegg, GermanyABF Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstr. 5, 82152 Planegg, GermanyOver the past decade, new emerging tobacco and nicotine-delivery products have changed the tobacco landscape. Especially, electronic cigarettes (ECs) have been suggested to be considered for tobacco harm reduction, reinforcing the need to identify novel biomarkers of exposure (BoE) specific to the EC use as this would complement exposure assessment and product compliance monitoring. Therefore, a sensitive LC-MS/MS method for the quantification of 1,2-propylene glycol (PG) and glycerol (G), the main e-liquid constituents, was established. PG and G were analyzed in plasma and urine samples from a clinical study comparing five nicotine product user groups, users of combustible cigarettes (CC), electronic cigarettes (EC), heated tobacco products (HTP), oral tobacco (OT), and oral/dermal nicotine delivery products (used for nicotine replacement therapy, NRT) with a control group of non-users (NU). Data demonstrate significantly elevated PG levels in urine and plasma in EC users compared to users of CC, HTP, NRT, OT as well as NU. In addition, PG in plasma and urine of vapers significantly correlated with nicotine (plasma) and total nicotine equivalents (urine), biomarkers reflecting product consumption, emphasizing the high specificity of PG as a BoE for EC consumption. We therefore suggest the use of PG as BoE in urine and/or plasma in order to monitor EC use compliance in exposure assessments.https://www.mdpi.com/2297-8739/8/10/180propylene glycolelectronic cigarettebiomarker of exposurecompliance marker
spellingShingle Therese Burkhardt
Nikola Pluym
Gerhard Scherer
Max Scherer
1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
Separations
propylene glycol
electronic cigarette
biomarker of exposure
compliance marker
title 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
title_full 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
title_fullStr 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
title_full_unstemmed 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
title_short 1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
title_sort 1 2 propylene glycol a biomarker of exposure specific to e cigarette consumption
topic propylene glycol
electronic cigarette
biomarker of exposure
compliance marker
url https://www.mdpi.com/2297-8739/8/10/180
work_keys_str_mv AT thereseburkhardt 12propyleneglycolabiomarkerofexposurespecifictoecigaretteconsumption
AT nikolapluym 12propyleneglycolabiomarkerofexposurespecifictoecigaretteconsumption
AT gerhardscherer 12propyleneglycolabiomarkerofexposurespecifictoecigaretteconsumption
AT maxscherer 12propyleneglycolabiomarkerofexposurespecifictoecigaretteconsumption